☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Cilest to be discontinued

The manufacturer of Cilest® (norgestimate and ethinyl estradiol) has written to healthcare professionals advising that this product will be discontinued with effect from July 2019.

The letter states that this was a commercial decision to exit the oral hormonal contraceptive market and it is stressed that the are no safety, efficacy or quality issues with the product. Current supplies are expected to last until mid-July 2019.

There are two alternative products that are currently available in the UK with the same active ingredients - Cilique® and Lizinna®.

Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and arrangements made to identify a suitable alternative.

Advert
Both Cilique and Lizinna (and other OCP brands) are available privately from UK regulated online clinics such as Dr Fox Pharmacy.
This product or service is not endorsed by Prescriber.org.uk

Share 'Cilest to be discontinued' by emailShare 'Cilest to be discontinued' on FacebookShare 'Cilest to be discontinued' on TwitterShare 'Cilest to be discontinued' on LinkedInShare 'Cilest to be discontinued' on reddit

atomic-wealth

22 Comments to “Cilest to be discontinued”

  1. […] الشركة المصنعة للدواء هو يانسن الشركة Silag / Janssen […]

    Pingback by دواعي استعمال أقراص سيليست Cilest والآثار الجانبية - يوميات — October 27, 2021 #
    Reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.

governor
governor
governor
governor